Mrc5 normal human fibroblasts

MRC5 normal human fibroblasts (ATCC, Manassas, VA, USA) and virus‐producing GP293 cells (Clontech, Mountain View, CA, USA) were cultured in Dulbecco′s modified Eagle′s medium (DMEM, Life Technologies, Carlsbad, USA) containing GlutaMAX and supplemented with 10% FBS (Sigma‐Aldrich, Saint Louis, USA) and 1% penicillin/streptomycin (Life Technologies). Dermal fibroblasts from patients with HGPS carrying the 1824 C > T mutation were obtained from the Progeria Research Foundation (HGADFN003; Peabody, MA) and the NIA Aging Cell Culture Repository (AG03199; New Jersey, USA); dermal fibroblasts from control patient without LMNA mutation were obtained from the NIA Aging Cell Culture Repository (AG03258; New Jersey, USA) and were cultured in DMEM supplemented with 20% FBS and 1% penicillin/streptomycin. Information of primary fibroblasts and their usage in the figures are displayed in Supporting Information Table S1. Cells were maintained at 37°C under a 5% CO₂ atmosphere. Pamidronate (506600, Merck Millipore, Billerica, USA), a FDPS inhibitor, was used at 5 µM. Nutlin‐3 (Sigma‐Aldrich), a p53 inducer, was used at 5 µM.

MRC5 normal human fibroblasts (ATCC, Manassas, VA, USA), and kidney 293 GP cells (Clontech, Mountain View, CA, USA) were cultured in Dulbecco′s modified Eagle′s medium (DMEM, Life Technologies, Carlsbad, USA) with GlutaMax and supplemented with 10% FBS (Sigma-Aldrich, Saint-Louis, USA) and 1% penicillin/streptomycin (ThermoFisher Scientific). XCT-790 (Medchem, HY-10426/CS-2413) was used at 150 nM. N-Acetyl-Cysteine (NAC) (A9165, Sigma-Aldrich) was used directly after infection at 1 mM. These compounds were renewed every two days.